Psyence Biomedical Ltd

자세한 내용은 Psyence Biomedical Ltd 회사

Psyence Biomedical Ltd is a Canada-based company, which develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The Company has partnered with iNGENu Pty Ltd (iNGENu) to conduct the Company’s clinical trial in palliative care. iNGENu is an Australia-based, globally focused contract research organization (CRO) with experience working in the psychedelic pharmaceutical drug development and clinical research industry. Its Phase IIb clinical trial, using PEX010, a 25mg naturally derived psilocybin drug candidate product in-licensed by the Company, in the palliative care setting.

회사 정보

종목 코드 PBM

회사 이름Psyence Biomedical Ltd

상장일Dec 10, 2021

CEODr. Neil Maresky

직원 수12

유형Ordinary Share

회계 연도 종료Dec 10

주소121 Richmond Street West Penthouse

도시TORONTO

증권 거래소NASDAQ Capital Market Consolidated

국가Canada

우편 번호M5H 2K1

전화17744604171

웹사이트

종목 코드 PBM

상장일Dec 10, 2021

CEODr. Neil Maresky

회사 임원

이름

이름/직위

직위

주식 보유

변동

Dr. Jody Aufrichtig

Chairman of the Board, Strategic Business Development Officer

--

Dr. Neil Maresky

Chief Executive Officer, Director

--

Mr. Warwick Corden-Lloyd

Chief Financial Officer

--

Mr. Marc Balkin

Independent Director

--

Mr. Christopher (Chris) Bull

Independent Director

--

Dr. Seth Feuerstein

Independent Director

--

이름

이름/직위

직위

주식 보유

변동

Dr. Jody Aufrichtig

Chairman of the Board, Strategic Business Development Officer

--

Dr. Neil Maresky

Chief Executive Officer, Director

--

Mr. Warwick Corden-Lloyd

Chief Financial Officer

--

Mr. Marc Balkin

Independent Director

--

Mr. Christopher (Chris) Bull

Independent Director

--

Dr. Seth Feuerstein

Independent Director

--

수익 분석

데이터 없음

데이터 없음

사업별

지역별

데이터 없음

주식 보유 통계

마지막 업데이트: Tue, Aug 19

주주

주주 유형

주주

비율

Parallel Advisors, LLC

38.56%

Sabby Management, LLC

2.85%

White Lion Capital LLC

1.76%

AdvisorShares Investments, LLC

0.62%

BofA Global Research (US)

0.47%

기타

55.74%

주주

비율

Parallel Advisors, LLC

38.56%

Sabby Management, LLC

2.85%

White Lion Capital LLC

1.76%

AdvisorShares Investments, LLC

0.62%

BofA Global Research (US)

0.47%

기타

55.74%

주주 유형

주주

비율

Investment Advisor

39.53%

Investment Advisor/Hedge Fund

2.85%

Venture Capital

1.83%

Corporation

0.48%

Research Firm

0.47%

기타

54.83%

기관 주식 보유

마지막 업데이트: Tue, Jul 1

보고 기간

기관 수

보유 주식

비율

변동

2025Q2

45

357.80K

50.17%

+181.11K

2025Q1

45

167.96K

26.60%

+69.68K

2024Q4

82

948.20K

24.27%

+587.08K

2024Q3

88

169.92K

15.90%

-186.51K

2024Q2

92

159.62K

36.84%

-203.47K

2024Q1

96

157.41K

35.61%

-211.56K

2023Q4

88

18.95K

16.18%

-253.66K

2023Q3

87

16.58K

55.18%

-252.44K

2023Q2

86

17.96K

50.97%

-264.02K

2023Q1

85

19.55K

55.14%

-329.89K

주주 활동

이름

보유 주식

비율

변동

Chg %

날짜

Sabby Management, LLC

32.21K

4.52%

+32.21K

--

Mar 31, 2025

White Lion Capital LLC

12.55K

1.76%

+12.55K

--

Dec 04, 2024

AdvisorShares Investments, LLC

4.45K

0.62%

+1.07K

+31.71%

Mar 31, 2025

Launchpad Ignition Holdings LLC

2.00K

0.28%

+2.00K

--

Mar 31, 2024

UBS Financial Services, Inc.

4.21K

0.59%

+2.62K

+164.01%

Mar 31, 2025

Tabula Rasa Ltd

1.45K

0.2%

-728.00

-33.47%

Mar 31, 2024

Stonehage Fleming Financial Services Holdings, Ltd.

562.00

0.08%

+562.00

--

Mar 31, 2025

Launchpad Capital Management Company, LLC

529.00

0.07%

+529.00

--

Mar 31, 2024

4.760USD

Psyence Biomedical Ltd

4.760

개요

회사

금융

분석